IN8bio, Inc.
INAB
$1.87
-$0.04-2.34%
NASDAQ
| 12/31/2025 | 09/30/2025 | ||||
|---|---|---|---|---|---|
| Revenue | -- | -- | |||
| Total Other Revenue | -- | -- | |||
| Total Revenue | -- | -- | |||
| Cost of Revenue | -- | -- | |||
| Gross Profit | -- | -- | |||
| SG&A Expenses | 28.02% | -31.36% | |||
| Depreciation & Amortization | -- | -- | |||
| Other Operating Expenses | -- | -- | |||
| Total Operating Expenses | 26.87% | -23.73% | |||
| Operating Income | -26.87% | 23.73% | |||
| Income Before Tax | -28.23% | 24.34% | |||
| Income Tax Expenses | -- | -- | |||
| Earnings from Continuing Operations | -28.23% | 24.34% | |||
| Earnings from Discontinued Operations | -- | -- | |||
| Extraordinary Item & Accounting Change | -- | -- | |||
| Minority Interest in Earnings | -- | -- | |||
| Net Income | -28.23% | 24.34% | |||
| EBIT | -26.87% | 23.73% | |||
| EBITDA | -29.80% | 22.81% | |||
| EPS Basic | 18.06% | 31.33% | |||
| Normalized Basic EPS | 18.07% | 31.32% | |||
| EPS Diluted | 18.06% | 31.33% | |||
| Normalized Diluted EPS | 18.07% | 31.32% | |||
| Average Basic Shares Outstanding | 56.50% | 10.16% | |||
| Average Diluted Shares Outstanding | 56.50% | 10.16% | |||
| Dividend Per Share | -- | -- | |||
| Payout Ratio | -- | -- | |||